Bristol Myers Squibb reported Phase 2 success for an engineered GPRC5D-directed CAR-T program, highlighting a potential new option for patients after relapse when standard approaches fall short. The company framed results as a step toward a more distinct treatment setting in multiple myeloma, a disease where sequencing and prior exposure increasingly determine outcomes. The report comes as the myeloma CAR-T landscape is crowded with multiple BCMA-directed and next-generation targets, increasing the importance of target biology and patient stratification. Analysts will likely focus on response depth, durability, and safety signals in the broader datasets. Investors are also watching how BMS positions this construct relative to competing therapies with different eligibility thresholds and time-to-treatment constraints.